Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.9.4379

Comparison Different Methods of Intraoperative and Intraperitoneal Chemotherapy for Patients with Gastric Cancer: A Meta-analysis  

Huang, Jin-Yu (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Xu, Ying-Ying (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Sun, Zhe (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Zhu, Zhi (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Song, Yong-Xi (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Guo, Peng-Tao (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
You, Yi (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Xu, Hui-Mian (Department of Surgical Oncology and General Surgery, First Hospital of China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.9, 2012 , pp. 4379-4385 More about this Journal
Abstract
Purpose: To investigate the efficacy and safety of intraperitoneal chemotherapy (IPC) for patients with gastric cancer and to compare effects between different regimens of IPC. Method: Randomized controlled trials comparing the effects of surgery plus intraperitoneal chemotherapy with surgery alone or comparing the efficacy between different regimens of intraperitoneal chemotherapy were searched for in Medline, Embase, Pubmed, the Cochrane Library and the Chinese BioMedical Disc and so on by two independent reviewers. After quality assessment and data extraction, data were pooled for meta-analysis using RevMan5.16 software. Tests of interaction were used to test for differences of effects among subgroups grouped according to different IPC regimens. Results: Fifteen RCTs with a total of 1713 patients with gastric cancer were included for quality assessment and data extraction. Ten studies were judged to be of fair quality and entered into meta-analysis. Hyperthermic intraoperative intraperitoneal chemotherapy (HR=0.60, P<0.01), hyperthermic intraoperative intraperitoneal chemotherapy plus postoperative intraperitoneal chemotherapy (HR=0.47, P<0.01) and normothermic intraoperative intraperitoneal chemotherapy (HR=0.70, P=0.01) were associated with a significant improvement in overall survival. Tests of interaction showed that hyperthermia and additional postoperative intraperitoneal chemotherapy did not impact on its effect. Further analysis revealed that intraperitoneal chemotherapy remarkably decrease the rate of postoperative hepatic metastasis by 73% (OR=0.27, 95% CI=0.12 to 0.67, P<0.01). However, intraperitoneal chemotherapy increased risks of marrow depression (OR=5.74, P<0.01), fever (OR=3.67, P=0.02) and intra-abdominal abscess (OR=3.57, P<0.01). Conclusion: The present meta-analysis demonstrates that hyperthermic intraoperative intraperitoneal chemotherapy and normothermic intraoperative intraperitoneal chemotherapy should be recommended to treat patients with gastric cancer because of improvement in overall survival. However, it is noteworthy that intraperitoneal chemotherapy can increase the risks of marrow depression, intra-abdominal abscesses, and fever.
Keywords
Gastric cancer; intraperitoneal chemotherapy; meta-analysis; hepatic metastasis; overall survival; safety;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219.   DOI
2 Brenner B, Shah MA, Karpeh MS et al (2006). A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol, 17, 1404-11.   DOI
3 Coffey DS, Getzenberg RH, DeWeese TL (2006). Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect. JAMA, 296, 445-8.   DOI
4 Deng HJ, Wei ZG, Zhen L et al (2009). Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao, 29, 295-7.
5 Ding W, Duan D, Sun G, Gu C (2007). Clinical observation on early intraperitoneal hypertherm ic perfusion chemotherapy in the treatment of stomach carcinoma after operation. Tumor, 27, 585-7.
6 Ferlay J, Shin HR, Bray F et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI
7 Fujimoto S, Takahashi M, Mutou T et al (1999). Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 85, 529-34.   DOI
8 Gao Z, Jiang Z, Zhou F (2002). Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang, 29, 294-5.
9 Hildebrandt B, Wust P, Ahlers O et al (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol, 43, 33-56.   DOI
10 Howell SB, Chu BB, Wung WE et al (1981). Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest, 67, 1161-70.   DOI
11 Kuramoto M, Shimada S, Ikeshima S et al (2009). Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg, 250, 242-6.   DOI
12 Matharu G, Tucker O, Alderson D (2011). Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg, 98, 1225-35.   DOI
13 Paoletti X, Oba K, Burzykowski T et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. JAMA, 303, 1729-37.   DOI
14 Nakao K, Otsuki Y, Akao Y et al (2000). The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc, 33, 44-50.   DOI
15 Newman E, Potmesil M, Ryan T et al (2005). Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol, 32, S97-100.   DOI
16 Ohtsu A, Yoshida S, Saijo N (2006). Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol, 24, 2188-96.   DOI
17 Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI
18 Ravichandran D, Lamah M, Carty NJ, Johnson CD (1995). Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma. Ann R Coll Surg Engl, 77, 431-6.   DOI
19 Roder JD, Bonenkamp JJ, Craven J et al (1995). Lymphadenectomy for gastric cancer in clinical trials: update. World J Surg, 19, 546-53.   DOI
20 Rosen HR, Jatzko G, Repse S et al (1998). Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol, 16, 2733-8.   DOI
21 Roti Roti JL (2008). Cellular responses to hyperthermia (40- 46 degrees C): cell killing and molecular events. Int J Hyperthermia, 24, 3-15.   DOI
22 Tierney JF, Stewart LA, Ghersi D et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.   DOI   ScienceOn
23 Shimoyama S, Shimizu N, Kaminishi M (1999). Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J Surg, 23, 284-91; discussion 91-2.   DOI
24 Speyer JL, Sugarbaker PH, Collins JM et al (1981). Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res, 41, 1916-22.   DOI
25 Takahashi T, Hagiwara A, Shimotsuma M et al (1995). Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg, 19, 565-9.   DOI   ScienceOn
26 Wei G, Fang GE, Bi JW et al (2005a). Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng, 24, 478-82.   DOI   ScienceOn
27 Wei G, Fang GE, Bi JW et al (2005b). [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. Ai Zheng, 24, 478-82.
28 Yan TD, Black D, Sugarbaker PH et al (2007). A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol, 14, 2702-13.   DOI
29 Yang XJ, Huang CQ, Suo T et al (2011). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol, 18, 1575-81.   DOI
30 Yonemura Y, de Aretxabala X, Fujimura T et al (2001). Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology, 48, 1776-82.   DOI
31 Yu W, Whang I, Chung HY et al (2001). Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg, 25, 985-90.   DOI   ScienceOn
32 Zhang GY, Chen XC, Pan K et al (2007). Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 10, 362-4.   DOI   ScienceOn
33 Zhang W, Su D, WANG K et al (1998). Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi, 27, 67-9.
34 Zuo Y, Xu M, Shen D et al (2004). Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhong Liu Za Zhi, 26, 247-9.